Saw Palmetto for PCOS: The Evidence Is Thinner Than the Marketing

Does Saw Palmetto Actually Work for PCOS?

Zero human trials have tested saw palmetto in women with PCOS, for any outcome — not testosterone, not hirsutism, not acne, not cycle length. Every recommendation you will find attached to a PCOS supplement list is extrapolated from research built for a different population and a different organ entirely: men with an enlarged prostate. That extrapolation is not automatically wrong, but it is the entire foundation, and it is worth knowing before you spend money on it.

The supplement itself is an extract of the berry of Serenoa repens, the American saw palmetto, sold for decades as a treatment for lower urinary tract symptoms in men. Over the past fifteen years it migrated into PCOS and hirsutism content on the strength of one biochemical claim, which is where the actual evidence needs to be checked.

What Is Saw Palmetto Supposed to Do to DHT?

Saw palmetto is marketed as a natural blocker of 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT) — the androgen most directly tied to hirsutism, jawline acne and androgenic hair loss in PCOS. That claim rests on a specific mechanism, and the most-cited study built to test it did not confirm it.

In a 1993 head-to-head laboratory comparison against finasteride — an actual 5-alpha-reductase-inhibiting drug — researchers measured how much of each compound it took to block the enzyme in human prostate tissue. Finasteride’s IC50 was 1 nanogram per millilitre; Permixon, a standardized saw palmetto extract, needed 5,600 ng/mL to do the same job — a difference of roughly 5,600-fold, at a concentration nobody could reach by taking a supplement. In castrated rats given testosterone or DHT, finasteride blocked prostate growth; Permixon did not. In a 7-day human trial arm of the same study, finasteride lowered serum DHT and Permixon did not. The authors’ own conclusion was that saw palmetto had “neither anti-androgen nor 5 alpha reductase inhibitory activity” at all — the opposite of the claim built on top of it.

What Do the Human Trials Actually Show?

The largest randomized trial of saw palmetto ever run found no benefit over placebo on any measure it tracked. 225 men over 49, given 160 mg of a standardized saw palmetto extract twice daily for one full year, showed no significant difference from placebo in symptom score, maximal urinary flow rate, prostate size, or PSA. That trial is not an outlier result buried in a small study — it is the best-powered saw palmetto trial that exists.

The pattern holds at the meta-analysis level too. A Cochrane review pooling 32 randomized trials in 5,666 men found Serenoa repens — even at double or triple the usual dose — did not outperform placebo on urinary symptom scores, peak urine flow, or prostate size, across trials running four to 72 weeks. An earlier, smaller trial of the same herbal blend in 44 men found a similar story: a slight edge over placebo that did not reach significance, with the study’s own authors describing the mechanism as “nonhormonal” and unexplained by any change in androgen receptor expression.

On safety, the same 225-man trial found saw palmetto well tolerated: 5.4% of the saw palmetto group had a serious adverse event versus 9.7% on placebo — not a significant difference — with no meaningful pattern of harm on bloodwork or sexual function. That reassurance is specific to adult men at 160 mg twice daily; it says nothing about a menstrual cycle, a pregnancy, or a developing endocrine system, which is a different question entirely.

Is There Any PCOS-Specific Evidence at All?

The closest thing to a PCOS trial for saw palmetto is a rat study, not a study in women, and it was only published in 2026. Forty-two letrozole-induced PCOS rats given saw palmetto extract at 160 or 320 mg/kg improved their hormone and lipid profiles, reduced oxidative stress markers, and showed more normal ovarian tissue under the microscope than untreated controls. That is a genuinely interesting signal for future research. It is also, unambiguously, an animal study — rodent hormone physiology does not map onto a human menstrual cycle closely enough to treat this as PCOS evidence in women, and the study’s own authors frame it as a starting point for further work, not a finished case.

The only report of saw palmetto’s hormonal effects in an actual human female runs in the opposite direction of the claim it is sold on. A 2015 case report describes a 10-year-old girl given a saw palmetto supplement for hirsutism who developed hot flashes; the flashes stopped when she discontinued the product, recurred when she restarted it, and she reached menarche about four months into treatment. The authors called it a probable case of endocrine disruption, not a benefit, and specifically flagged pediatric use as needing far more caution than it is currently given.

Does Saw Palmetto Lower DHT in Women?

No trial has measured this directly. Every DHT-lowering claim made for saw palmetto in women is inferred from a mechanism that failed its own 1993 test in prostate tissue and castrated rats — not measured in a woman’s blood, ever, at any dose. If a product description tells you saw palmetto “blocks DHT” and cites a study, check whether that study was done in a person or a petri dish, and whether the result the study actually reported was positive. In the founding study for this claim, it was not.

Saw Palmetto vs Spearmint Tea for Hirsutism

If you are weighing the two most commonly recommended “natural” options for PCOS-related hirsutism against each other, they are not in the same evidence class. Spearmint tea has two small randomized trials in women, one of which found blood testosterone dropped within 30 days without a matching drop in the clinical hirsutism score in that window — thin evidence, but evidence, in the actual target population. Saw palmetto has no randomized trial in women of any kind, for hirsutism or anything else. Set side by side, spearmint tea is a weak trial base; saw palmetto is closer to no trial base at all.

Who Should Not Take Saw Palmetto?

Saw palmetto is also a poor candidate if what you actually want is a decision backed by a trial in PCOS. It joins a short list of supplements sold on a plausible-sounding hormone story that the trial base does not back up — DIM is the other clear example, though resveratrol clears that particular bar with one real, well-powered human trial behind its testosterone claim, bioavailability problems aside. Before spending a supplement budget on hormone-related skin or hair symptoms, it is worth checking our ranked review of which PCOS supplements actually clear the trial-evidence bar, starting with what has real trial data for PCOS acne specifically.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS), the name a 2026 global consensus of more than 50 organisations gave the same condition. None of the evidence above changes with the rename; this article uses PCOS because that is still what most readers search.